The tumor microenvironment drives cancer development by fostering cell-cell communication, ECM remodeling, immune evasion, angiogenesis, and metabolic reprogramming. These processes collectively promote tumor progression, metastasis, and therapy resistance through key pathways such as TGF-β, Wnt (wingless-type MMTV integration site family), Hedgehog, and hypoxia-induced signaling, highlighting the need for targeted interventions like anti-stromal agents, metabolic inhibitors, and cancer stem cell (CSC)-directed immunotherapies.

Tumor cells drive profound molecular, cellular, and physical changes within the TME, shaping its dynamic and evolving nature. This structured environment comprises tumor cells alongside a range of non-malignant host cells, including immune cells, cancer-associated fibroblasts (CAFs), endothelial cells, and pericytes embedded in a vascularized ECM.

Once considered passive participants in tumorigenesis, these host cells are now recognized as key drivers of cancer progression and potential therapeutic targets. The composition and function of the TME vary based on the tumor’s organ of origin, intrinsic cancer cell properties, tumor stage, and patient-specific factors^1,2.

Components of the TME

The TME is predominantly defined by its composition, ie, immune cells, stromal cells, and non-cellular components, which regulate tumor progression, immune evasion, angiogenesis, and metastasis through complex interactions².

Immune cells

The immune cells in the TME play an essential role in either inhibiting or supporting tumor progression, depending on the context. This dual nature highlights the complexity of their interactions within the TME. Immune cells are generally classified into two main groups: adaptive and innate immune cells. Adaptive immunity is triggered by distinct antigens and relies on immunological memory to assess threats and amplify immune responses through T cells, B cells, and natural killer (NK) cells. In contrast, innate immunity provides a rapid, non-specific defense response against foreign antigens within hours of exposure through cells such as macrophages, neutrophils, and dendritic cells².

T cells

T cells play a vital role in TME, with distinct subtypes influencing tumor progression. The subtype CD8+ cytotoxic T cells recognize abnormal tumor antigens and target cancer cells for destruction and support the suppression of angiogenesis via interferon (IFN)-γ secretion, often correlating with a favorable prognosis. The T helper-1 (Th-1) cells are pro-inflammatory CD4+ T cells that support CD8+ T cells through interleukin (IL)-2 and IFN-γ secretion, contributing to positive outcomes in several types of cancers. In contrast to its normal function, the regulatory T (Treg) cells in the TME suppress antitumor immunity, promote tumor growth by secreting IL-2 and growth factors, and interact with stromal cells to support cancer progression².

The T cells immune landscape in the TME is classified into:

• Immune infiltrated, where the T cells are evenly distributed within the tumor.
• Immune excluded, where T cells remain at the tumor’s periphery.
• Immune silent, where tumors lack immune cell infiltration, indicating an absence of immune response².

B cells

B cells are immune cells involved in antibody production, antigen presentation, and cytokine secretion. Although fewer B cells infiltrate the TME compared to T cells, they play a significant role in tumorigenesis. B cells contribute to the formation of tertiary lymphoid structures within the TME, which facilitate interactions between T and B cells and are linked to favorable outcomes in breast cancer, melanoma, and ovarian cancer. B cells exert antitumorigenic effects by presenting antigens, producing antitumor antibodies, and secreting cytokines like IFN-γ to enhance cytotoxic responses².

However, they can also have pro-tumorigenic roles, particularly in bladder, prostate, and renal cell cancers, where their presence correlates with poor prognosis. Regulatory B cells promote tumor progression by secreting IL-10 and transforming growth factor-beta (TGF-β), fostering immune suppression in macrophages, neutrophils, and cytotoxic T cells².

NK cells

The natural killer (NK) cells continuously “patrol” the bloodstream, identifying and targeting virally infected or tumor cells. Their functions fall into two main categories, that is, they either directly kill the tumor cells through cell-mediated cytotoxicity or respond by secreting inflammatory cytokines. While NK cells are highly effective at eliminating tumor cells in circulation and preventing metastasis, their efficiency is significantly lower within the TME due to immunosuppressive factors, inhibitory receptor interactions, limited infiltration, metabolic constraints, and tumor evasion mechanisms^2,3,4.

Macrophages

As key players in the innate immune system, macrophages regulate immune responses through phagocytosis and antigen presentation. Additionally, they also contribute to tissue repair and wound healing. Monocyte-derived macrophages are classified into two subtypes: M1 macrophages, which exhibit inflammatory and tumor-killing properties, and M2 macrophages, which are immunosuppressive and aid in wound healing².

Within tumors, the TME preferably promotes the M2 phenotype by inducing hypoxia and releasing cytokines such as IL-4, supporting tumor growth and progression. Some tumors are densely infiltrated with macrophages, constituting up to 50% of the tumor mass. In breast, lung, and gastric cancers, high macrophage infiltration is generally linked to poor prognosis. Additionally, macrophages often cluster around blood vessels in the TME, where they release vascular endothelial growth factor A (VEGF-A) to stimulate angiogenesis².

Neutrophils

Neutrophils are the body’s first line of defense against various pathogens and constitute up to 70% of circulating leukocytes. In cancer, their role is dual-faceted, ie, they either inhibit or facilitate tumor growth depending on the tumor type and stage. During early tumor development, neutrophils are recruited to the TME, where they enhance inflammation by releasing cytokines and reactive oxygen species (ROS), leading to tumor cell apoptosis².

However, in later stages, neutrophils shift toward promoting tumor progression by remodeling the ECM, secreting VEGF, and producing matrix metalloproteinase-9 (MMP-9) to drive angiogenesis, tumor expansion, and local invasion².

Dendritic cells

Dendritic cells are essential antigen-presenting cells that identify, capture, and present antigens to T cells within secondary lymphoid organs such as lymph nodes. By linking innate and adaptive immunity, these cells play a pivotal role in initiating pathogen-specific T cell responses. Within the TME, environmental signals influence dendritic cell function, either promoting an immune response against tumor cells or fostering immune tolerance.

Pro-inflammatory signals such as type I interferons, IL-12, and GM-CSF support dendritic cell maturation and enhance their ability to activate effector T cells. In contrast, immunosuppressive cytokines such as IL-10, TGF-β, and VEGF impair dendritic cell maturation and function, skewing them toward a tolerogenic phenotype that fails to elicit effective antitumor immunity².

Explore this detailed poster summarizing the intricate cross-talk between the tumor microenvironment and the immune system to better understand their dynamic interactions.

Other cells

Stromal cells: During tumorigenesis, the tumor cells recruit stromal cells from surrounding endogenous tissues. The composition of stromal cells differs across tumor types but commonly includes endothelial cells, fibroblasts, adipocytes, and stellate cells. In the TME, the stromal cells interact dynamically with the tumor cells and drive tumor progression. Upon recruitment to the TME, stromal cells release various factors that affect angiogenesis, cell proliferation, invasion, and metastasis².

Endothelial cells: Vascular endothelium, a thin monolayer of endothelial cells, plays an essential role in angiogenesis, nutrient delivery, immune cell transport, and metabolic homeostasis. Early-stage tumors rely on passive diffusion for gas exchange and nutrient transport. However, once they reach a volume of 1-2 mm³, hypoxia and acidity trigger the need for a dedicated blood supply. Hypoxia-inducible factors (HIFs) drive angiogenesis by promoting the secretion of pro-angiogenic factors such as platelet-derived growth factor (PDGF), epidermal growth factor (EGF), and VEGF. Despite this, the blood vessels formed within tumors are often immature and prone to leakage².

Beyond angiogenesis, endothelial cells contribute to cancer progression by undergoing endothelial-mesenchymal transition (EMT) into CAFs, driven by TGF-β and bone morphogenetic protein (BMP). This transition enhances tumor cell migration and invasion. In metastasis, tumor cells enter the vasculature through intravasation by disrupting EC barriers. The structurally weak tumor vasculature facilitates extravasation, allowing cancer cells to spread to distant sites².

Cancer-associated fibroblasts: Cancer-associated fibroblasts (CAFs) are the key components of the tumor stroma, mediating interactions between cancer cells and the TME. While primarily derived from tissue-resident fibroblasts, CAFs can also originate from endothelial cells, adipocytes, pericytes, stellate cells, and mesenchymal stem cells derived from bone marrow².

Typically, fibroblasts transition into myofibroblasts during wound healing, a process driven by TGF-β signaling. In tumors, cancer and stromal cells mimic this process by secreting factors such as TGF-β, PDGF, and fibroblast growth factor 2 (FGF2), leading to CAF accumulation. CAF accumulation is often linked to poor prognosis in many cancers, including colorectal cancer. However, in certain cancers like breast and lung cancer, a high CAF presence (desmoplasia) can correlate with better survival².

CAFs shape the TME by promoting tumor proliferation, metastasis, angiogenesis, ECM remodeling, and immunosuppression. They facilitate EMT, a key step in metastasis, by secreting TGF-β and degrading E-cadherin through MMP-3, enabling cancer cell invasion. CAFs also regulate angiogenesis by releasing VEGF via MMP-13 activity and contribute to immune evasion by secreting immunosuppressive cytokines and chemokines, further supporting tumor progression².

Adipocytes: Adipocytes regulate energy balance by storing excess energy as fat. Obesity, affecting over 40% of cancer patients, is a significant risk factor for various cancers, including breast, pancreatic, and ovarian cancer².

In TME, adipocytes exert their effects through the secretion of metabolites, enzymes, hormones, growth factors, and cytokines. In cancer, adipocytes engage in dynamic interplay with tumor cells to promote cancer progression. In breast cancer, where the tissue is largely composed of white adipose tissue (WAT), adipocytes play a vital role by undergoing lipolysis and releasing free fatty acids that cancer cells utilize for energy, membrane synthesis, and bioactive lipid production.

Adipocyte-derived leptin supports tumor growth by directly enhancing breast cancer cell proliferation and indirectly activating macrophages. As an endocrine organ, WAT can drive breast cancer metastasis to the liver and lungs through paracrine signaling. Additionally, adipocytes also contribute to ECM remodeling by secreting metalloproteases such as MMP-1, MMP-7, MMP-10, MMP-11, and MMP-14, thereby promoting tumor progression and metastasis².

Stellate cells: Stellate cells are mesenchymal-derived stromal cells found in the liver and pancreas that remain quiescent until activated by tissue injury. Upon activation, they transform into myofibroblasts, entering the cell cycle and contributing to ECM remodeling. A defining feature of stellate cells is their vitamin A storage in lipid droplets, which are essential for ECM production and modification².

In the liver, hepatic stellate cells (HSCs) reside in perisinusoidal and portal areas, making up about 15% of liver mass. In hepatocellular carcinoma (HCC), tumor-derived TGF-β activates HSCs, leading to ECM remodeling and secretion of pro-angiogenic factors such as VEGF-A and MMP-2. Similarly, in pancreatic ductal adenocarcinoma (PDAC), pancreatic stellate cells (PSCs) contribute to the formation of dense fibrotic stroma (desmoplasia). PSC activation, often triggered by vitamin A depletion, enhances migration, proliferation, and cytokine secretion, driving PDAC progression and promoting hypoxic TME².

Non-cellular components

The non-cellular components of the TME, including the ECM, extracellular vesicles like exosomes, and signaling molecules such as chemokines, cytokines, and growth factors, play essential roles in tumor progression by providing structural support, facilitating communication between cancer and stromal cells, promoting angiogenesis, modulating immune responses, and driving metastasis through various biochemical and cellular interactions.

Extracellular matrix

ECM plays a vital role in the TME by providing structural support and facilitating tumor cell dissemination. Composed of collagen, fibronectin, elastin, and laminin, the ECM can make up to 60% of a tumor’s mass. Excessive collagen deposition and fibroblast infiltration contribute to desmoplasia, which is associated with poor prognosis².

While various cells within the TME secrete ECM components, CAFs are the primary source. MMPs remodel the ECM by breaking down its proteins, promoting tumor progression and metastasis. Additionally, the ECM serves as a reservoir for cytokines and growth factors, such as VEGF, FGF, PDGF subunit B (PDGFB), and TGF-β, which are released by proteolytic enzymes to support tumor growth and angiogenesis².

Interstitial fluid

The tumor interstitial fluid is the local perfusate of the tumor microenvironment that surrounds all cells in the tumor parenchyma. Acting as the interface between tumor cells and the circulation, the tumor interstitial fluid supplies essential nutrients, ions, proteins, electrolytes, growth factors, and signaling molecules necessary for tumor invasion, migration, and metastasis.

Tumor interstitial fluid plays a crucial role in regulating cancer cell metabolism and biology. The nutrient-starved tumor microenvironment forces cancer cells to adapt metabolically, often relying on compensatory mechanisms to overcome nutrient limitations. Studies have shown that pancreatic cancer cells experience amino acid stress due to low arginine levels, leading to de novo synthesis as a survival strategy. Similarly, researchers have identified metabolic shifts in metastasizing cancer cells, such as breast cancer cells in the brain increasing serine and lipid synthesis, or renal carcinomas in the lung upregulating arginine production to cope with environmental constraints.

Beyond cancer cell metabolism, tumor interstitial fluid also influences antitumor immunity by shaping immune cell function. Metabolite analyses of melanoma tumor interstitial fluid reveal that key nutrients like glucose are depleted, impairing T cell signaling and metabolism. Additionally, accumulated metabolites such as lactate, lipids, and potassium can suppress effector T cell proliferation while promoting immunosuppressive Treg cell functions. However, not all metabolites negatively affect immune function, certain nucleotides in melanoma tumor interstitial fluid have been shown to enhance T cell activity, presenting potential opportunities for therapeutic interventions.

Extracellular vesicles (exosomes)

Exosomes are small vesicles, ranging from 30 nm to 200 nm, that carry proteins, RNA, DNA, and lipids, mirroring the characteristics of their originating cells. Within the TME, they act as the key mediators of communication between tumor cells and stromal cells. Exosomes contribute to tumor progression by promoting inflammation, angiogenesis, and metastasis. Hypoxic conditions enhance the production of exosomes by tumor cells, further driving the conversion of stromal cells into CAFs and supporting tumor development².

Signaling molecules

The TME also houses various signaling molecules, primarily cytokines, chemokines, and growth factors, that are secreted by the TME’s cellular components to facilitate intercellular communication that influences tumor development, invasion, angiogenesis, and immune response.

Chemokines: Chemokines are small signaling molecules that regulate the directed migration of leukocytes and other cells. They play important roles in biological processes such as morphogenesis, wound healing, and cancer development. Within tumors, chemokines contribute to various functions, including growth, EMT, angiogenesis, immune cell recruitment, and resistance to therapy.

For example, CXCL12 (also known as SDF-1) promotes tumor growth and metastasis through its interaction with CXCR4, facilitating EMT and the homing of cancer cells to distant organs. CCL2 recruits monocytes and macrophages to the tumor microenvironment, often promoting immune suppression and tumor progression. CXCL8 (IL-8) supports angiogenesis and has been associated with enhanced tumor invasiveness and resistance to chemotherapy. These and other chemokines help shape the tumor microenvironment, influencing both tumor cell behavior and host immune responses⁶.

Chronic inflammation further promotes tumor progression, as chemokines secreted by cancer cells and immune cells facilitate cellular trafficking into the TME. Depending on the context, chemokines can either enhance immune infiltration and inflammation or support immune evasion and tumor advancement. This duality is largely determined by the types of chemokines produced, the receptors expressed on surrounding cells, and the composition of the TME.

In an immunologically active TME, chemokines such as CXCL9, CXCL10, and CCL5 promote the recruitment of cytotoxic T lymphocytes, NK cells, and dendritic cells, leading to enhanced immune surveillance and antitumor responses. For instance, CXCL9/CXCL10-CXCR3 signaling is associated with better prognosis in several cancers due to robust CD8⁺ T cell infiltration⁷.

Conversely, in an immunosuppressive or advanced TME, chemokines like CCL2, CCL22, and CXCL12 can recruit regulatory T cells (T_regs), myeloid-derived suppressor cells (MDSCs), and tumor-associated macrophages (TAMs), which inhibit effective immune responses and facilitate tumor growth and metastasis. For example, CCL22 attracts CCR4⁺ T_regs, dampening antitumor immunity, while CXCL12 can form a barrier that prevents T cell infiltration and supports tumor cell survival^6,7.

Cytokines: Cytokines are small signaling proteins produced by various cell types, including chemokines, interferons, interleukins, lymphokines, and tumor necrosis factors (TNF). A range of different cytokines play vital roles in tumor processes such as growth, EMT, angiogenesis, immune cell infiltration, and resistance to therapeutics⁸.

Several pro-inflammatory cytokines, such as IFN-γ, TNFα, TGF-β, and ILs, contribute to cancer initiation, progression, and metastasis. Within the TME, cytokines can have both pro-inflammatory and anti-inflammatory effects, promoting immune infiltration and inflammation while also facilitating immune evasion and tumor progression⁸.

Growth factors: Growth factors function as cellular signaling molecules that regulate processes such as cell growth, differentiation, metabolism, and function. While they play essential roles in normal cellular regulation, they also influence tumor growth and progression in cancer. Key growth factors present in the TME include EGFs, PDGFs, insulin-like growth factors (IGFs), FGFs, VEGFs, and TGF-β⁸.

The primary mode of communication between tumor cells and the TME occurs through these growth factors and their respective receptors. When a growth factor binds to its receptor on the cell surface, it triggers intracellular signaling cascades that alter gene expression. Both epithelial and mesenchymal cells release growth factors into the TME, and dysregulated cellular responses to these factors contribute to malignant transformation⁸.

Biological features and interactions in the TME

TME drives cancer progression through cell-to-cell communication between tumor and stromal cells, immune evasion, and angiogenesis mediated by VEGF-driven vascular remodeling, collectively enhancing tumor invasion, migration, and metastasis.

Cell-to-cell communication

The interaction between tumor cells and the TME is driven by bidirectional communication, where both tumor cells and stromal cells influence each other’s behavior. Tumor cells release cytokines, chemokines, and growth factors that recruit and modify stromal cells, such as fibroblasts, immune cells, adipocytes, and endothelial cells. In turn, stromal cells secrete signaling molecules that enhance tumor cell proliferation, survival, and metastasis⁹.

For example, CAFs, a dominant stromal component in many cancers, produce growth factors like FGF and HGF, promoting tumor growth and resistance to therapy. Moreover, CAFs remodel the ECM, creating a microenvironment that facilitates tumor invasion and dissemination^9.

CAFs drive tumor invasiveness by altering the biochemical and physical properties of the ECM. They upregulate MMPs, particularly MMP2, MMP9, and MMP14, which degrade ECM components such as collagen and fibronectin, effectively clearing a path for migrating tumor cells. In parallel, CAFs secrete ECM proteins like fibronectin and tenascin-C, which reorganize the matrix into aligned, stiffened tracks that promote directional cancer cell migration. The increased deposition of type I collagen and lysyl oxidase (LOX)-mediated crosslinking stiffens the ECM, enhancing mechanotransduction signals that favor cell motility and invasiveness^10,11.

Recent research has highlighted the significance of exosomes in mediating communication within the TME. These nanosized vesicles transport proteins, lipids, and nucleic acids, enabling tumor-derived exosomes to reprogram recipienT cells and foster a pro-tumorigenic milieu. For example, exosomes can deliver oncogenic proteins and microRNAs to neighboring cells within the TME, thereby stimulating tumor growth and conditioning distant sites for metastasis⁹.

This dynamic interplay of the function of various cells, regulated by intricate cell-to-cell communication involves a network of reciprocal interactions where tumor cells and their microenvironment mutually reinforce malignant processes. A deeper understanding of these mechanisms may lead to the identification of novel therapeutic targets aimed at disrupting these interactions and impeding cancer advancement⁹.

Immune evasion and angiogenesis

Immune cells within the TME can contribute to immune evasion and modulation, enabling tumor progression and metastasis. Certain immune cells, such as TAMs and MDSCs, undergo alterations that favor tumor survival. For example, tumor-derived factors drive TAMs toward M2-like macrophages, which support tumor growth while suppressing antitumor immunity. Similarly, MDSCs inhibit the cytotoxic functions of T cells and NK cells, thereby weakening immune surveillance and facilitating tumor escape⁹.

The TME actively promotes angiogenesis, fostering the development of new blood vessels necessary for tumor growth and metastatic spread. A key regulator of this process is VEGF, which is produced by both tumor and stromal cells. Elevated VEGF levels increase vascular permeability and lead to the formation of disorganized, leaky tumor vasculature, ultimately facilitating tumor cell intravasation into the bloodstream^9.

Role of the TME in cancer development

TME drives cancer development by fostering cell-cell communication, ECM remodeling, immune evasion, angiogenesis, and metabolic reprogramming.

Tumorigenesis and progression

Angiogenesis, EMT, and metastasis are the three essential interconnected phases in the development and progression of cancer. Essentially, the TME acts as a complex environment that facilitates the progression of cancer through these interconnected processes. The TME regulates angiogenesis, EMT, and metastasis by providing a complex network of signaling molecules, extracellular matrix components, and interacting cell types that can directly influence cancer cell behavior, promoting tumor growth, invasion, and dissemination to distant organs^9,12.

Angiogenesis

The fibroblasts, macrophages, and tumor cells in the TME can secrete pro-angiogenic factors like VEGF, which stimulate the formation of new blood vessels, allowing tumors to access nutrients and oxygen for growth and expansion. Hypoxic conditions within the tumor may also trigger the expression of pro-angiogenic factors, creating a positive feedback loop to promote angiogenesis. Further, the ECM composition of the TME can influence angiogenesis by providing structural support and signaling cues for endothelial cells to form new blood vessels⁹.

Epithelial-to-mesenchymal transition

The cell-to-cell interactions in the TME are governed by cytokines, growth factors, fibroblasts, and chemokines that are secreted by both tumor cells and stromal cells, which activate important signaling pathways involved in cancer progression. Notably, TGF-β functions as a double-edged sword, inhibiting tumor initiation in early stages but later promoting metastasis by triggering epithelial-to-mesenchymal transition. Through EMT, epithelial cells acquire mesenchymal characteristics, including heightened migratory ability, invasiveness, and resistance to apoptosis, ultimately facilitating tumor dissemination⁹.

Metastasis

By facilitating angiogenesis and EMT, the TME allows tumor cells to detach from the primary site, invade surrounding tissues, enter circulation, and colonize distant organs, leading to metastasis. The TME in distant organs is primed by factors secreted from the primary tumor, creating a conducive environment for tumor cell adhesion and colonization and facilitating metastasis. The TAMs secrete pro-inflammatory cytokines and chemokines to facilitate tumor cell migration and invasion. Further, the MMPs secreted by both tumor cells and stromal cells within the TME can degrade the ECM, enabling cancer cell migration and invasion^9,12.

Contribution to resistance to therapy

TME plays a vital role in establishing multidrug resistance through immune evasion, altering drug delivery, and promoting a cancer stem cell (CSC) phenotype. Immunosuppressive components, including TAMs, MDSCs, and T_regs, create a pro-tumorigenic environment by inhibiting cytotoxic CD8+ T lymphocytes (CTLs) and NK cells. TAMs, especially M2-type, secrete immunosuppressive cytokines such as IL-10 and TGF-β, along with angiogenic factors like VEGF and MMPs. These molecules impair drug efficacy by dampening antitumor immunity, promoting abnormal vasculature that limits drug delivery, and enhancing ECM remodeling that creates physical barriers to drug penetration¹³.

MDSCs suppress T cells via arginase 1 (ARG1) and nitric oxide synthase 2 (NOS2), while T_regs inhibit immune responses through IL-10 and TGF-β, further reducing the effectiveness of immune-based therapies. IL-10 and TGF-β inhibit T cell activation and proliferation by downregulating antigen presentation and co-stimulatory signals, while also promoting T cell exhaustion. ARG1 depletes L-arginine, an essential amino acid for T cell receptor signaling and function, thereby impairing T cell responses. NOS2 produces nitric oxide, which induces T cell apoptosis and disrupts signaling pathways necessary for cytotoxic activity¹³. T cell

Soluble factors in the TME, such as VEGF, IL-6, and Wnt family member 16B (WNT16B), enhance tumor survival and chemoresistance through paracrine signaling. Additionally, metabolic reprogramming within the TME, driven by hypoxia and acidosis, upregulates hypoxia-inducible factor-1 (HIF-1), glycolysis, and multidrug resistance protein 1 (MDR1), which encodes P-glycoprotein, reducing intracellular drug accumulation and promoting multidrug resistance¹³.

P-glycoprotein (MDR1) is a membrane-bound transport protein that functions to pump out a variety of drugs and toxins from inside the cell. This reduces the intracellular concentration of therapeutic agents, contributing to multidrug resistance in cancer cells by limiting drug efficacy.

The Warburg effect and acidic TME further support tumor progression, immune suppression, and drug sequestration in lysosomes¹³.

TME significantly impairs drug absorption by creating physical and biochemical barriers. The ECM, enriched with collagen, fibronectin, and proteoglycans, becomes dense and stiff in tumors, hindering drug penetration. Tumor-associated fibroblasts (TAFs) further remodel the ECM by secreting MMPs and promoting hyaluronic acid synthesis, increasing interstitial pressure and reducing drug diffusion¹³.

Abnormal tumor vasculature contributes to drug resistance by being highly permeable yet inefficient in delivering therapeutic agents, leading to hypoxia and metabolic stress. Hypoxia stabilizes HIF-1, promoting angiogenesis via VEGF and activating drug resistance pathways. Lysyl oxidase (LOX) enzymes enhance ECM stiffness and further restrict drug transport¹³.

Additionally, TME interactions sustain CSCs, which induce resistance to therapeutics due to their quiescent state, high drug efflux ability via ATP-binding cassette (ABC) transporters, and enhanced DNA repair mechanisms. Cytokines secreted by TAFs, such as hepatocyte growth factor (HGF) and IL-6, reinforce CSC survival and self-renewal, promoting tumor recurrence and chemoresistance¹³.

Tumor heterogeneity and the microenvironment

Tumor heterogeneity, shaped by spatial and temporal variations in the TME, along with dynamic CSC niches, drives cancer progression, resistance to therapy, and metastasis through mechanisms such as EMT, hypoxia, and key signaling pathways (Notch, Wnt, Hedgehog). This highlights the need for targeted therapeutic strategies, including anti-stromal agents, TGF-β inhibitors, and CSC-directed immunotherapies like CAR-T cells and cancer vaccines.

Spatial and temporal heterogeneity

Spatial heterogeneity is a key characteristic of the TME, where its components vary significantly across different tumor regions. This heterogeneity is like ecological systems, where diverse environmental conditions lead to distinct adaptations. In tumors, vascularized and hypoxic regions coexist, influencing cancer cell genotypes and drug responses¹⁴.

For example, in glioblastoma, EGFR-amplified cells thrive in hypoxic areas, while PDGFRA-amplified cells are found near blood vessels, highlighting environmental adaptation. Understanding spatial heterogeneity can help identify factors driving tumor progression and resistance, drawing parallels to ecological studies on invasive species and their dispersal patterns¹⁴.

Temporal heterogeneity in the TME refers to dynamic changes that occur over time due to tumor evolution, treatment responses, and interactions with surrounding cells. Tumors continuously adapt to external pressures, including hypoxia, immune surveillance, and therapy, leading to shifts in cellular composition, gene expression, and metabolic activity. For instance, cancer cells may initially respond to chemotherapy but later develop resistance through genetic mutations or epigenetic modifications. Similarly, immune cell infiltration and cytokine levels fluctuate, influencing tumor progression and drug efficacy¹⁵.

Cancer stem cell niches

CSC niches play a vital role in regulating CSC maintenance, self-renewal, differentiation, and plasticity, contributing to tumor progression, therapy resistance, and recurrence. These niches, composed of cancer cells, stromal cells, ECM, and signaling molecules, provide a supportive microenvironment that enables CSC survival and function¹⁶.

CSC behavior is influenced by both genetic/epigenetic modifications and external niche interactions. Key niche factors such as hypoxia contribute to CSC maintenance by regulating pathways like HIF-1α, which promotes tumor progression, angiogenesis, and therapy resistance. CSCs also exhibit metastatic potential, and they can establish new niches in distant tissues by modulating stromal factors like periostin¹⁶.

The EMT plays an essential role in CSC dissemination, enhancing invasiveness, therapy resistance, and metastatic potential. EMT is regulated by hypoxia and transcription factors (eg, Snail, Twist, Zeb1/2), which downregulate epithelial markers while promoting mesenchymal characteristics¹⁶.

Therapeutic strategies targeting the CSC niche focus on overcoming therapy resistance and tumor relapses, which are major challenges in cancer treatment. CSCs persist post-therapy due to their quiescence, anti-apoptotic mechanisms, and efficient DNA repair systems. Key resistance mechanisms include hypoxia, EMT, and CSC-associated signaling pathways such as Notch, Wnt, and Hedgehog¹⁶.

Targeting EMT as a means of managing cancer is being extensively researched, given the ability of EMT to enhance stemness and chemoresistance. Anti-stromal agents like plerixafor have shown promise in restoring chemosensitivity. TGF-β signaling inhibition, exemplified by fresolimumab, has demonstrated improved immune responses and survival in metastatic breast cancer. HGF-MET (mesenchymal-epithelial transition factor) signaling is another potential target, with anti-MET antibodies showing efficacy in overcoming resistance¹⁶.

Hypoxia sustains CSC properties by activating HIFs and drug transporters (ABCB1, ABCG2). Agents like acriflavine and vatalanib target these pathways to enhance chemosensitivity. Clinical trials have explored γ-secretase inhibitors for Notch pathway inhibition, ipafricept for Wnt signaling, and Hedgehog pathway antagonists in various cancers¹⁶.

CSC-directed immunotherapies, including cancer vaccines and CAR-T cell therapies, are emerging. A dendritic cell vaccine demonstrated promising results in metastatic lung cancer, while CAR-T therapies targeting CD19/CD22/CD33 are being investigated in leukemia¹⁶.

Advances in research and future directions

Emerging therapies targeting TME, epigenetic modifications, microbiota interactions, and combination immunotherapies are advancing cancer treatment.

Emerging research techniques

Emerging therapies targeting the TME represent a promising frontier in cancer treatment by disrupting the tumor-supportive environment to enhance treatment efficacy. Key strategies include stromal reprogramming, immune modulation, ECM-targeting agents, and personalized medicine approaches¹⁷.

Stromal reprogramming focuses on modifying CAFs and mesenchymal stem cells to reduce their tumor-promoting roles, with TGF-β inhibitors showing potential in preclinical models. However, challenges remain in selectively targeting tumor-associated stromal cells without affecting normal tissues¹⁷.

Immune microenvironment modulation employs checkpoint inhibitors, cytokine therapies, CAR-T cells, and TAM-targeting agents to enhance antitumor immunity. While these strategies show significant value, overcoming immunosuppressive mechanisms within the TME remains a challenge, necessitating combination therapies¹⁷.

ECM-targeting agents aim to alter the tumor microarchitecture to improve drug penetration and inhibit cancer cell invasion. However, clinical translation has been difficult due to specificity concerns and potential side effects¹⁷.For example, matrix metalloproteinase inhibitors (MMPIs) have been developed to disrupt ECM remodeling and limit tumor invasion. However, early broad-spectrum MMPIs failed in clinical trials due to the lack of specificity, unexpected toxicity, and use in late-stage cancers where MMPIs may no longer play central role¹⁸.

Personalized medicine leverages specific biomarker profiles and patient-derived xenografts to tailor treatments based on individual tumor characteristics, improving therapeutic precision and reducing toxicity¹⁷.

Despite their potential, TME-targeting therapies face challenges such as tumor heterogeneity, therapy-induced resistance, and potential off-target effects. Future research will focus on refining predictive models, identifying new therapeutic targets, and integrating AI-driven approaches to enhance personalized treatment strategies¹⁷.

Role of the tumor microbiome in shaping the microenvironment

The microbiota consists of microorganisms such as bacteria, viruses, fungi, and archaea that inhabit various mucosal surfaces, including the gut, oral cavity, skin, and genital tract. While commensal microbiota generally benefits the host, dysbiosis can contribute to disease and even carcinogenesis¹⁹.

The gut microbiota has been extensively studied due to its abundance, but research on microbiota in other tissues has been limited by technological challenges. Recent advancements in sequencing and imaging techniques have enabled the identification of microbiota in tumors previously considered sterile, such as breast, lung, liver, and bone cancers¹⁹.

Intratumoral microbiota is now recognized as a key component of the TME, influencing tumor heterogeneity, immune modulation, and treatment outcomes. These microbes, along with their metabolites and residues, shape a unique “tumor microbe microenvironment” that affects tumor progression, metastasis, and immune responses. Depending on their composition and host conditions, intratumoral microbiota can have both pro- and antitumorigenic effects, influencing immune activation, ROS production, and tumor mutations¹⁹.

The therapeutic potential of microbiota is gaining interest, with applications in cancer prognosis, targeted drug delivery, and immune modulation. Certain microbiota-based treatments, such as BCG for bladder cancer and T-VEC for melanoma, are already in clinical use. Further research into the tumor-microbiota interaction may lead to novel microbiota-based cancer therapies¹⁹.

Additionally, the intratumoral microbiota includes diverse organisms beyond bacteria, such as fungi, viruses, and parasites, which may contribute to oncogenesis. For example, Malassezia species are linked to pancreatic cancer. Understanding the complex interplay between specific microbes and the TME may provide novel avenues for cancer treatment and prevention¹⁹.

Innovative therapies on the horizon

Epigenetic targeting of the TME is a promising approach in cancer therapy.  Combining immunotherapy with TME modulation enhances tumor immunogenicity and vascular normalization, leading to stronger antitumor responses.

Epigenetic targeting of TME components

One of the primary strategies involves targeting DNA methylation, a key epigenetic mechanism that regulates gene silencing. Inhibition of DNA methylation can reprogram immunosuppressive cells such as tumor-associated macrophages (TAMs) and enhance the activity of natural killer (NK) cells and CD8⁺ T cells. Hypomethylating agents such as 5-azacytidine and 5-aza-2’-deoxycytidine (5-aza-dC) have demonstrated synergistic antitumor effects when used alongside histone deacetylase inhibitors (HDACis) or ICIs. These combinations modulate immune cell function and sensitize tumors to chemotherapy, thereby improving therapeutic responses²⁰.

Another avenue is targeting histone modifications, which affect chromatin structure and gene expression. Histone-modifying enzymes play pivotal roles in T helper (Th) cell differentiation, regulatory T cell (Treg) function, and tumor-infiltrating lymphocyte (TIL) activity. Selective HDAC inhibitors, including ACY-1215 and entinostat, have been shown to impair the suppressive activity of Tregs while boosting the cytotoxic function of CD8⁺ T cells. Furthermore, EZH2 inhibitors enhance NK cell cytotoxicity, and HDAC3-selective inhibitors have been linked to improved CD8⁺ T cell responses, collectively contributing to a more effective antitumor immune environment²⁰.

In addition to DNA and histone modifications, RNA modifications have emerged as new targets in immuno-oncology. Enzymes such as fat mass and obesity-associated protein (FTO), AlkB homolog 5 (ALKBH5), and methyltransferase-like 3 (METTL3) regulate mRNA metabolism and immune signaling. Inhibition of these enzymes can improve T cell-mediated killing of tumor cells and enhance responsiveness to ICIs. Small-molecule inhibitors, including STM2457 and thiram, have shown potential in preclinical models by suppressing tumor growth and mitigating immune escape mechanisms²⁰.

For greater precision, CRISPR/dCas9-based epigenome editing offers a targeted method to modulate gene expression without the broad off-target effects associated with traditional epi-drugs. By fusing a catalytically inactive dCas9 to engineered histone acetyltransferases or methyltransferases, researchers can selectively activate or repress gene expression at specific loci. This technology presents a powerful tool for fine-tuning the immune response in cancer therapy²⁰.

Lastly, epigenetic modulation is being applied to enhance adoptive cell therapies (ACT) such as CAR-T and CAR-NK cell therapies. Preconditioning these therapeutic cells with epi-drugs like EZH2 inhibitors has been shown to improve their persistence, functionality, and antitumor efficacy. Moreover, clinical evidence suggests that disruption of ten-eleven translocation methylcytosine dioxygenase 2 (TET2) can enhance CAR-T cell responses, further supporting the integration of epigenetic strategies into ACT protocols²⁰.

Combined therapies leveraging immunotherapy and TME modulation

Checkpoint blockade immunotherapy holds promise for cancer treatment but is often hindered by an immunosuppressive TME, particularly due to CAFs and defective tumor vasculature. To overcome these barriers, researchers developed CAF-targeted nanoemulsions (AE-MGNPs) incorporating melittin, an immunogenic cell death (ICD) inducer with antifibrotic properties, and nitric oxide donor S-nitrosoglutathione for vascular normalization²¹.

AE-MGNPs exhibited dual functionality by inducing ICD to enhance tumor immunogenicity and reprogramming the TME by inactivating CAFs, reducing ECM deposition, and normalizing tumor vessels. This led to improved infiltration of CTLs and suppression of immunosuppressive cell recruitment. In CAF-rich colorectal tumor models, combining AE-MGNPs with anti-CTLA-4 antibodies significantly enhanced antitumor immune responses, demonstrating a potent strategy to improve immunotherapy efficacy²¹.

Challenges in research and clinical translation

The TME hinders effective drug delivery via nanocarriers via multiple barriers, including abnormal vasculature, rigid ECM, hypoxia, acidic pH, excess glutathione and ROS levels, and immune suppression. Tumor angiogenesis produces leaky, tortuous vessels with poor lymphatic drainage, leading to high interstitial fluid pressure that limits nanoparticle penetration. The tumor stroma, dominated by CAFs, generates excessive ECM components that physically restrict drug transport²².

Metabolic alterations within tumors further complicate treatment, as hypoxia stabilizes HIFs, promoting therapy resistance, while metabolic shifts to anaerobic glycolysis increase acidity, enhancing tumor survival. The immunosuppressive TME features TAMs, MDSCs, and T_regs, which inhibit antitumor immunity by suppressing CD8+ T cell responses. Tumor cells also evade immune detection by downregulating major histocompatibility complex expression and upregulating checkpoint molecules like PD-L1²².

FAQs

How does the tumor microenvironment influence cancer progression?

The tumor microenvironment (TME), consisting of stromal cells, immune cells, blood vessels, and extracellular matrix components, creates a supportive niche that promotes tumor growth, invasion, and immune evasion through hypoxia, acidic pH, and abnormal signaling. These conditions drive angiogenesis, suppress antitumor immunity, and enhance metastatic potential, making the TME a critical target for cancer therapy.

What role do immune cells play in the tumor microenvironment?

Immune cells in the tumor microenvironment can either suppress or promote tumor progression by influencing cancer cell survival, immune evasion, and therapy resistance. While cytotoxic immune cells initially target tumors, cancer cells often evade immune surveillance, leading to the development of immunotherapy strategies like immune checkpoint inhibitors and CAR-T cell therapy.

How does the tumor microenvironment contribute to drug resistance?

The tumor microenvironment hinders drug penetration, promotes cell survival by enhancing proliferation and resistance to apoptosis, and drives therapy resistance through non-genetic mechanisms such as epigenetic modifications, ultimately altering disease progression and skewing clinical indicators.

References

1. de Visser, K.E., Joyce, J.A., The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell. 41, 374–403 (2023).
2. Anderson, N.M., Simon, M.C. The tumor microenvironment. Current Biology. 30, R921–R925 (2020).
3. Masmoudi, D., Villalba, M., Alix-Panabières, C. Natural killer cells: the immune frontline against circulating tumor cells. Journal of Experimental & Clinical Cancer Research. 44, 118 (2025).
4. Wu, S.Y., Fu, T., Jiang, Y.Z., et al. Natural killer cells in cancer biology and therapy. Molecular Cancer. 19, 120 (2020).
5. Apiz Saab, J.J., Muir, A. Tumor interstitial fluid analysis enables the study of microenvironment–cell interactions in cancers. Current Opinion in Biotechnology. 83, 102970 (2023).
6. Nagarsheth, N., Wicha, M.S., Zou, W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nature Reviews Immunology. 17, 559–572 (2017).
7. Kohli, K., Pillarisetty, V.G. & Kim, T.S. Key chemokines direct migration of immune cells in solid tumors. *Cancer Gene Ther.*29, 10–21 (2022).
8. Zhang, X., Ma, H., Gao, Y., et al. The tumor microenvironment: Signal transduction. Biomolecules. 14, 438 (2024).
9. Biray Avci, C., Goker Bagca, B., Nikanfar, M., et al. Tumor microenvironment and cancer metastasis: molecular mechanisms and therapeutic implications. Frontiers in Pharmacology. 15, 1442888 (2024).
10. Erdogan, B., Webb, D.J. Cancer-associated fibroblasts modulate growth factor signaling and extracellular matrix remodeling to regulate tumor metastasis. Biochemical Society Transactions. 45, 229–236 (2017).
11. Son, G.M., Kwon, M.S., Shin, D.H., et al. Comparisons of cancer-associated fibroblasts in the intratumoral stroma and invasive front in colorectal cancer. Medicine (Baltimore). 98, e15164 (2019).
12. de Visser, K.E., Joyce, J.A. The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell. 41, 374–403 (2023).
13. Meng, L., Zheng, Y., Liu, H., et al. The tumor microenvironment: A key player in multidrug resistance in cancer. Oncologie. 26, 41–58 (2023).
14. Yuan, Y. Spatial heterogeneity in the tumor microenvironment. Cold Spring Harbor Perspectives in Medicine. 6, a026583 (2016).
15. Ge, R., Wang, Z., Cheng, L. Tumor microenvironment heterogeneity: An important mediator of prostate cancer progression and therapeutic resistance. NPJ Precision Oncology. 6, 31 (2022).
16. Ju, F., Atyah, M.M., Horstmann, N., et al. Characteristics of the cancer stem cell niche and therapeutic strategies. Stem Cell Research & Therapy. 13, 233 (2022).
17. El-Tanani, M., Rabbani, S.A., Babiker, R., et al. Unraveling the tumor microenvironment: Insights into cancer metastasis and therapeutic strategies. Cancer Letters. 591, 216894 (2024).
18. Winer, A., Adams, S., Mignatti, P. Matrix metalloproteinase inhibitors in cancer therapy: Turning past failures into future successes. Molecular Cancer Therapeutics. 17, 1147–1155 (2018).
19. Zhang, S., Huang, J., Jiang, Z., et al. Tumor microbiome: Roles in tumor initiation, progression, and therapy. Molecular Biomedicine. 6, 9 (2025).
20. Yang, J., Xu, J., Wang, W.  et al.  Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets.  Sig Transduct Target Ther.  8, 210 (2023).
21. Shen, W., Li, Y., Yang, Z.  et al.  Tumor microenvironment reprogramming combined with immunogenic enhancement by nanoemulsions potentiates immunotherapy.  J Nanobiotechnol.  22, 154 (2024).
22. Zhou, Y., Chen, X., Cao, J., et al. Overcoming the biological barriers in the tumor microenvironment for improving drug delivery and efficacy. Journal of Materials Chemistry B. 31, (2020).